Navigation Links
Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
Date:9/8/2009

LONDON, Sept. 8 /PRNewswire/ -- The 2009 Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award is presented to Pronova BioPharma ASA. The company's first commercialised product is the first and only EU-and FDA-approved omega-3 derived prescription drug. Branded Omacor in Europe and Asia and Lovaza in the USA, the product is a prescribed adjunct to diet for the treatment of elevated levels of triglycerides in humans. In addition, Omacor/Lovaza has the approval in certain markets for treatment of the secondary prevention of post-myocardial infarction.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Pronova BioPharma has demonstrated excellence in financial management. The growth in sales in 2008 as compared to 2007 was 28.3 per cent. The company witnessed a growth of 38.5 per cent in 2009 Q1 over 2008 Q1. The total production of active pharmaceutical ingredients (API) were 615 tonnes, 918 tonnes, and 1201 tonnes, while shipments were 593 tonnes, 929 tonnes, and 1185 tonnes in 2006, 2007, and 2008, respectively. The growth in production and shipment is phenomenal and is reflective of the strong demand for Omacor/Lovaza.

Pronova BioPharma's return on assets (ROA) improved from 16.8 per cent in 2007 to 34.5 per cent in 2008. This was based on continued strong growth and commercial progress, further efficiency improvements and optimisation of manufacturing facilities at the Sandefjord plant.

"The company has dramatically improved its return on equity (ROE) and return on capital employed (ROCE) over the years 2006 to 2008; in 2006, the ROCE and ROE were a negative 3.2 per cent and negative 4.4 per cent respectively, improving to 11.2 per cent and 34.5 per cent respectively in 2008," said Shrik
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Aging Population, Heightened Consumer Awareness Propel U.S. Bone and Joint Health Ingredients, Says Frost & Sullivan
2. Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan
3. U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan
4. Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award
5. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
6. Frost & Sullivan: Growing Healthcare Tourism in Malaysia
7. A Wound that Does Not Heal: Frost & Sullivan Reveals the Impact of Chronic Ulcers on the European Healthcare System
8. Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009
9. Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record
10. Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan
11. Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 National Geographic questioned in an article ... of remembrance is getting lost in the swirl of summer ... and prompted some research and analysis on the subject based ... A statistical evaluation of around 180 ecards shared by Americans, ... the emotions of fun and celebration. In the modern ...
(Date:5/24/2013)... Lake City, UT (PRWEB) May 24, 2013 ... MonaVie Latin America, as a new member of the Ethics ... “I am proud to have been elected to this council ... ethical basis of the direct selling industry,” says Patrocinio. , ... a positive contributor to Brazil’s economy. The direct selling industry ...
(Date:5/24/2013)... This report “EpiCast Report: Meningococcal Disease ... the risk factors and global trends for meningococcal disease ... Spain, UK, Australia, and Brazil). It includes a 10-year ... by age (<1, 1–4, 5–14, 15–24, 25–44, 45–64, and ... in these markets. The other serogroups, namely serogroups A ...
(Date:5/24/2013)... According to the new market research report “Micro ... 2016)” published by MarketsandMarkets, global micro irrigation system market ... of year 2010 and is expected to reach $3,414.7 ... from 2011 to 2016. , Browse:, , ... Figures , 370 pages and in-depth Table ...
(Date:5/24/2013)... Just about any bodyweight training program includes a variety of ... Dallas, GA that uses a variety of bodyweight conditioning circuits ... used enough. , “The medicine ball pushup is ... By keeping your hands on a medicine ball, the core ... much harder than a standard pushup. This unique bodyweight chest ...
Breaking Medicine News(10 mins):Health News:Is Memorial Day More Than A Three-Day Weekend 2Health News:MonaVie Brazil Executive Elected to Ethics Board of ABEVD 2Health News:Meningococcal Disease Market Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com 2Health News:Meningococcal Disease Market Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com 3Health News:Meningococcal Disease Market Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com 4Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2
... Million Americans Have Parkinson,s Disease, Roughly ... ... 21 Accolade, a Texas-based home,healthcare and hospice provider, observes ... Parkinson,s disease.,Accolade,s innovative short-term program enables people living with the,disease ...
... proved more beneficial than individual grief counseling, study finds ... experience the unexpected death of a parent after a ... finding that has major implications for helping children deal ... "Often children who have lost a parent are given ...
... than 6 millimeters in diameter appear more likely to ... in the April issue of Archives of Dermatology, one ... diameter guidelines currently used by dermatologists to screen for ... method to screen for melanoma, according to background information ...
... Decisions on Bottom Line Return at 3rd Annual ... Pharmaceutical Market Research Summit, NEW ... the pharmaceutical analytics company Eularis, will be,delivering a presentation on ... Research and Decisions on Bottom Line Return., ...
... of West Nile Virus and Other Diseases, SACRAMENTO, ... in hand. Coinciding with the launch of mosquito season, ... to April 25,2008 West Nile Virus and Mosquito and ... a mosquito-borne disease that can result in,debilitating cases of ...
... suggests , , MONDAY, April 21 (HealthDay News) -- The ... disease than women appear during the adolescent years, according a ... , "This is not what we would have predicted," said ... the University of Minnesota Children,s Hospital, and lead author of ...
Cached Medicine News:Health News:April is National Parkinson's Disease Awareness Month 2Health News:April is National Parkinson's Disease Awareness Month 3Health News:Treating PTSD Helps Kids Deal With Loss 2Health News:Larger skin lesions appear more likely to be melanomas 2Health News:Eularis to Address Making the Right Research Decision for ROI 2Health News:State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week 2Health News:Heart Disease Risks Hit Boys in Teens 2
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" ... specialty products, announced today that Dr. Robert Grieve ... Jason Napolitano , executive vice president and ... MicroCap Conference, which is being held May 30, 2013 in ... Hyatt Hotel. The Company,s presentation is scheduled ...
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
Super High Density, multi-frequency, phased array burr hole transducer. Excellent for taking biopsy samples and shunt placements....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
Medicine Products: